Shield Therapeutics plc (STX) Ordinary Shares 1.5p
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Shield Therapeutics reports strong US progress
7 December 2023 13:11
(Sharecast News) - Iron deficiency-focussed pharmaceuticals company Shield Therapeutics announced significant achievements in the US commercialisation of Accrufer on Thursday.
-
Shield's Canadian partner files new drug submission for Accrufer
21 March 2022 11:58
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced on Monday that KYE Pharmaceuticals has submitted a new drug submission to Health Canada, for the regulatory review and...
-
Shield Therapeutics revenue falls in line with expectations
17 February 2022 15:51
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics reported total 2021 revenue of £1.5m in a trading update on Thursday, in line with market expectations.
-
Shield Therapeutics enters Accrufer licensing deal in Canada
5 January 2022 13:43
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics has entered into an exclusive licence agreement for 'Accrufer', it announced on Wednesday, with KYE Pharmaceuticals in...
-
Shield shares surge on expansion of US coverage for Accrufer
16 December 2021 15:21
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics updated the market on progress made on payer coverage of 'Accrufer' in the United States on Thursday.
-
Shield Therapeutics appoints chief medical officer
27 September 2021 14:26
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced on Monday that Dr Jose Menoyo is joining its senior executive team as vice-president and chief medical officer, with...
-
Shield Therapeutics swings to losses in first half
17 August 2021 12:00
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics reported first-half revenues of £0.5m in its interim results on Tuesday, falling from £8.9m year-on-year.
-
Shield Therapeutics inks exclusive licence for 'Accrufer' in Korea
12 August 2021 12:25
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics has entered into an exclusive licence agreement for 'Accrufer', it announced on Thursday, with Korea Pharma in South...
-
Shield Therapeutics appoints industry veteran Greg Madison as CEO
28 May 2021 13:37
(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced on Friday that Greg Madison has been appointed as its chief executive officer, with effect from 1 June.
Company announcements Announcements
-
Audited results for the year ended 31 Dec 2023
10 May 2024 15:30
Shield Therapeutics
-
Business Update for Q1 2024
30 April 2024 07:00
Shield Therapeutics
-
Notice of Results
16 April 2024 07:00
Shield Therapeutics
-
Unaudited Full Year Trading Update
21 February 2024 07:00
Shield Therapeutics
-
Appointment of new Chief Financial Officer
9 January 2024 07:00
Shield Therapeutics
-
Q3 2023 U.S. Commercial Highlights
7 December 2023 07:00
Shield Therapeutics
-
PDMR Transaction Notification
27 November 2023 17:24
Shield Therapeutics
-
Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team
15 November 2023 07:30
Shield Therapeutics
-
Chief Financial Officer Transition
12 October 2023 07:00
Shield Therapeutics
-
Result of REX Retail Offer
3 October 2023 15:00
Shield Therapeutics
-
Block listing Interim Return
3 October 2023 07:00
Shield Therapeutics
-
Completion of SWK Financing
3 October 2023 07:00
Shield Therapeutics
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.